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OBJECTIVES This study investigated the clinical outcomes of patients with ST-segment elevation
myocardial infarction (MI) treated with sirolimus-eluting stents (SESs) or with conventional
bare stents.
BACKGROUND The clinical impact of SES implantation for patients with ST-segment elevation MI is
currently unknown.
METHODS Primary angioplasty was performed with SESs in 186 consecutive patients with acute MI who
were compared with 183 patients treated with bare stents. The incidence of death,
reinfarction, and repeat revascularization was assessed at 30 and 300 days.
RESULTS Postprocedure vessel patency, enzymatic release, and the incidence of short-term adverse
events were similar in both the sirolimus and the bare stents (30-day rate of death,
reinfarction, or repeat revascularization: 7.5% vs. 10.4%, respectively; p  0.4). Stent
thrombosis was not diagnosed in any patient in the sirolimus group and occurred in 1.6% of
patients treated with bare stents (p  0.1). At 300 days, treatment with SESs significantly
reduced the incidence of combined adverse events (9.4% vs. 17%; hazard ratio [HR] 0.52
[95% confidence interval (CI) 0.30 to 0.92]; p  0.02), mainly due to a marked reduction in
the risk of repeat intervention (1.1% vs. 8.2%; HR 0.21 [95% CI 0.06 to 0.74]; p  0.01).
CONCLUSIONS Compared to conventional bare stents, the SESs were not associated with an increased risk
of stent thrombosis and were effective in reducing the incidence of adverse events at 300 days
in unselected patients with ST-segment elevation acute MI referred for primary
angioplasty. (J Am Coll Cardiol 2004;43:704–8) © 2004 by the American College of
Cardiology Foundationp
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Voutine stent implantation has been advocated for patients
ith acute myocardial infarction (MI) referred for primary
ngioplasty, with superior results compared to balloon
ilation (1–3). However, the late clinical efficacy is still
ampered by the occurrence of in-stent restenosis and the
eed for repeat intervention.
Sirolimus-eluting stents (SESs) have proven to be effec-
ive in reducing late restenosis compared to conventional
tenting in elective patients (4–6). We have recently shown
n a relatively small consecutive series of cases that SES
mplantation in patients with acute MI was safe and
ssociated with an extremely low (zero) incidence of angio-
raphic restenosis at six months (7). However, the clinical
enefit of SESs in comparison to conventional stent im-
lantation remains currently unknown. Therefore, we eval-
ated the long-term clinical outcomes of a large series of
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Manuscript received November 4, 2003; revised manuscript received November 20,J003, accepted November 24, 2003.atients with acute MI treated with primary angioplasty
tilizing either SESs or conventional metal stents.
ETHODS
ince April 2002, SES implantation (Cypher, Johnson &
ohnson-Cordis unit, Cordis Europa NV, Roden, The
etherlands) has been utilized as the strategy of choice for
atients treated with percutaneous intervention in our in-
titution (8). Up until January 2003, a total of 186 consec-
tive patients with ST-segment elevation acute MI have
een treated with primary angioplasty utilizing exclusively
ESs and were included in the present report. The first 89
atients of the present series were included in an angio-
raphic substudy, of which the results have been reported
reviously (7). A control group for comparison was com-
osed of 183 consecutive patients with ST-segment eleva-
ion acute MI treated with conventional bare stents in the
eriod immediately before the introduction of SESs. The
ollowing bare metal stents were used: BX Sonic or BX
elocity in 53% (Cordis, Johnson & Johnson, Warren, Newersey); Multi-Link Penta in 22% (Guidant Corp., Santa
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February 18, 2004:704–8 SES for Acute MIlara, California); Multi-Link Tetra in 6% (Guidant
orp.); R-Stent in 6% (Orbus Medical Technologies, Fort
auderdale, Florida), and other stents in 12%. In both study
hases, all patients were enrolled regardless of the clinical or
natomical presentation, including patients admitted with
ardiogenic shock (defined as persistent systolic blood pres-
ure90 mm Hg, or the need of vasopressors or intra-aortic
alloon pumping required to maintain blood pressure 90
m Hg with evidence of end-organ failure and elevated left
entricular filling pressures). Therefore, the total study
opulation comprised all 369 consecutive patients with
T-segment elevation acute MI undergoing primary angio-
lasty with either bare stents or SESs in the two study
hases, respectively. Patients with angioplasty after failed
hrombolytic therapy were excluded from the present anal-
sis. This study protocol was approved by the local ethics
ommittee, and written informed consent was given by
very patient.
The final interventional strategy, as well as the utilization
f periprocedural glycoprotein IIb/IIIa inhibitors and anti-
hrombotic medications, was entirely left to the discretion of
he operator. Baseline and postprocedure anterograde flow
ere evaluated off-line according to the Thrombolysis In
yocardial Infarction (TIMI) criteria (9) by cardiologists
linded to both the stent group and to the clinical outcomes.
lopidogrel was recommended for at least one month in the
ontrol group. In the SES group, clopidogrel was prescribed
or three months, unless one of the following was present (in
hich case clopidogrel was maintained for at least six
onths): multiple SES implantation (3 stents), total
tented length 36 mm, bifurcation stenting, and in-stent
estenosis.
Patients were prospectively followed for the occurrence of
ajor adverse cardiac events: 1) all-cause death, 2) nonfatal
I, or 3) target vessel revascularization. Reinfarction was
iagnosed by recurrent symptoms and/or new electrocardio-
raphic changes in association with re-elevation of the
reatine kinase (CK) and CK-MB levels of 1.5 times the
revious value, if within 48 h, or3 times the upper normal
imit, if after 48 h from the index infarction (1,7). Target
essel revascularization was defined as a repeat intervention
surgical or percutaneous) driven by any lesion located in the
ame epicardial vessel treated at the index procedure.
hrombotic stent occlusion was angiographically docu-
ented as a complete occlusion (TIMI flow grade 0 or 1) or
flow-limiting thrombus (TIMI flow grade 1 or 2) of a
Abbreviations and Acronyms
CI  confidence interval
CK  creatine kinase
HR  hazard ratio
MI  myocardial infarction
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarctionreviously successfully treated artery. Routine angiographic [ollow-up was obtained only for patients treated with SESs
nrolled during the first six months; results of this subanaly-
is have been previously reported (7).
Continuous variables were presented as mean  standard
eviation, and were compared using the Student unpaired t
est. Categorical variables were presented as counts and
ercentages and compared with the Fisher exact test.
urvival free of adverse events was estimated using the
aplan-Meier method and differences between curves were
valuated by the log-rank test. Cox proportional hazards
urvival models were used to assess risk reduction. Multi-
ariate analyses were performed to identify independent
redictors of long-term major adverse cardiac events. Base-
ine and procedural characteristics associated with the inci-
ence of adverse events at univariate analysis (p value for
election 0.2) were tested for their multivariate predictive
alue (tested variables: SES utilization, diabetes, cardiogenic
hock, multivessel disease, culprit vessel, pre-procedure
IMI flow, postprocedure TIMI flow, current smoking).
he final model was built by backward stepwise variable
election with an entry and exit criteria set at the p  0.05
nd p  0.1 levels, respectively.
ESULTS
aseline characteristics were similar between both study
roups, except by an older age and a lower incidence of
revious MI in the sirolimus group (Table 1). Procedural
haracteristics differed between both groups in terms of the
tilization of glycoprotein IIb/IIIa inhibitors (sirolimus:
7% vs. bare stents: 56%; p  0.01) and the number of
tents implanted (sirolimus: 1.9  1.2 vs. bare stents: 1.7 
.0; p  0.03). As defined by the study protocol, the
uration of clopidogrel prescription was longer for patients
ith sirolimus stents (Table 1).
No significant differences existed in the 30-day outcomes
etween patients treated with sirolimus or bare stents (Table
). Stent thrombosis was diagnosed in three patients (1.6%)
reated with bare stents and was not detected in the SES
roup (p  0.1) (Table 2).
At 300 days, no differences were noted between both
tudy groups in the incidence of death and death or
einfarction (Table 2). However, the incidence of 300-day
ajor adverse events was significantly lower in the sirolimus
tent group compared to the bare stent group (9.4% vs. 17%,
espectively; hazard ratio [HR] 0.52 [95% confidence inter-
al (CI) 0.30 to 0.92]; p  0.02) (Table 2, Fig. 1), mainly
ue to a marked reduction in the risk of repeat intervention
1.1% vs. 8.2%, respectively; HR 0.21 [95% CI 0.06 to
.74]; p  0.01). A multivariate analysis was performed to
djust for baseline and procedural imbalances between the
tudy groups (Table 3). Sirolimus-eluting stent utilization
as identified as an independent predictor of 300-day
eath, reinfarction, or repeat revascularization (HR 0.53
95% CI 0.29 to 0.95]; p  0.03).
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SES for Acute MI February 18, 2004:704–8ISCUSSION
he main finding of the present study was that SES
mplantation was effective in reducing the incidence of
dverse events at 300 days in unselected patients with
T-segment elevation acute MI, compared to conventional
Table 1. Baseline and Procedural Characteristi
Implantation
Male (%)
Age, yrs  SD
Diabetes (%)
Current smoking (%)
Previous myocardial infarction (%)
Previous angioplasty (%)
Previous bypass surgery (%)
Coronary disease
Single-vessel (%)
Double-vessel (%)
Triple-vessel (%)
Cardiogenic shock (%)
Time from symptom onset to angioplasty, h  SD
Infarct-related vessel
Right coronary artery (%)
Left anterior descending (%)
Left circumflex artery (%)
Left main coronary artery (%)
Bypass graft (%)
TIMI flow baseline
Grade 0/I (%)
Grade II (%)
Grade III (%)
TIMI flow after angioplasty
Grade 0/I (%)
Grade II (%)
Grade III (%)
Number of stents  SD
Glycoprotein IIb/IIIa inhibitor (%)
Clopidogrel prescription, months  SD
Peak CK, IU/l  SD*
Peak CK-MB, IU/l  SD†
*Upper limit of normal 199 IU/l. †Upper limit of normal 23
CK  creatine kinase; SD  standard deviation; SES 
Infarction.
able 2. Kaplan-Meier Estimates of Adverse Events at 30 Days
nd at 300 Days
Bare Stents
(n  183)
SES
(n  186)
p
Value
0-Day outcomes
Death (%) 5.5 5.9 1.0
Death or nonfatal reinfarction (%) 7.1 6.5 0.8
Target vessel revascularization (%) 4.4 1.1 0.1
Any event (%) 10.4 7.5 0.4
Stent thrombosis (%)* 1.6 0 0.1
00-Day outcomes
Death (%) 8.2 8.3 0.8
Death or nonfatal reinfarction (%) 10.4 8.8 0.5
Target vessel revascularization (%) 8.2 1.1 0.01
Any event (%) 17.0 9.4 0.02
Angiographically documented stent thrombosis.
SES  sirolimus-eluting stents. iare stenting. Furthermore, the risk of subacute thrombosis
ithin the first 30 days did not appear higher compared
ith bare metal stents. Sirolimus-eluting stents were asso-
Patients Treated With Bare Stents or SES
Bare Stents
(n  183)
SES
(n  186) p Value
79 75 0.4
57  12 60  12 0.04
12 11 0.9
47 46 0.8
24 14 0.03
9 7 0.4
3 2 0.3
0.3
48 55
29 27
24 18
10 13 0.3
3.0  2.7 3.2  1.9 0.6
0.3
30 37
57 53
10 8
1 2
2 —
0.7
73 73
15 17
13 10
0.5
4 2
17 15
79 83
1.7  1.0 1.9  1.2 0.03
56 37 0.01
2.1  1.5 3.7  2.1 0.01
3,957  5,135 3,126  3,126 0.1
319  230 296  255 0.5
imus-eluting stents; TIMI  Thrombolysis In Myocardial
igure 1. Survival free of reinfarction or target vessel revascularization in
he sirolimus-eluting stent and conventional stent groups. CI confidencecs of
IU/l.
sirolnterval.
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February 18, 2004:704–8 SES for Acute MIiated with a relative reduction of 48% in the risk of death,
einfarction, or repeat intervention and a relative reduction
f 79% in the risk of repeat intervention at 300 days.
In our series, reperfusion treatment with SESs was
ssociated with similar rates of vessel patency, enzymatic
elease, and 30-day complications compared to bare stents.
he death rate and the incidence of death or reinfarction
ere similar in both study groups, but somewhat higher
han those reported in randomized trials with selected
atients (1,2). These findings most probably reflect the
nrestrictive inclusion criteria of our series (10), which
requently enrolled patients not included in randomized
tudies, as, for instance, cardiogenic shock, multivessel
isease, and unprotected left main lesions. Importantly,
tent thrombosis has not been identified in any patient
reated with sirolimus stents and occurred in three controls
1.6%), with no statistical difference between the groups.
lthough the incidence of stent thrombosis in the bare stent
roup was at a somewhat higher range, our results in this
roup were not discrepant from historical series with con-
entional stents (1,2,11–13).
Coronary stenting for the treatment of acute MI has been
imited by the need of late repeat intervention, which has
een reported to occur in approximately 9% of cases at six
onths, ranging from 3.6% to 22.7% (1–3). The incidence
f repeat intervention after conventional stenting in our
eries (8.2%) was in line with these previous figures. Con-
ersely, patients treated with SES implantation clearly had a
educed risk of reintervention at 10 months. Of note,
etween 30 days and 10 months, no additional patient was
eferred for repeat revascularization, which is consistent
ith the lack of angiographic restenosis after sirolimus stent
mplantation, as previously shown in a subset of patients
rom the present population (7).
The peri- and postprocedural antiplatelet therapeutic
cheme differed between patients treated with either bare or
irolimus stents in our series. Patients in the sirolimus group
eceived fewer glycoprotein IIb/IIIa inhibitors but had a
onger clopidogrel prescription time. However, none of
able 3. Multivariate Predictors of 300-Day Major Adverse
ardiac Events
Hazard
Ratio
95%
Confidence
Interval
p
Value
ES utilization 0.53 0.29–0.95 0.03
ardiogenic shock 3.31 1.72–6.34 0.01
ulprit vessel left main coronary 6.05 1.60–22.87 0.01
ulprit vessel left anterior descending 2.02 1.10–3.71 0.02
ostprocedure TIMI flow grade 0.01
Grade 0/I (reference) 1.00 —
Grade II 0.29 0.11–0.76
Grade III 0.17 0.07–0.40
urrent smoking 0.57 0.31–1.02 0.06
ES  sirolimus-eluting stents; TIMI  Thrombolysis In Myocardial Infarction.hese characteristics were identified as independent predic-ors influencing the outcomes of patients. The impact of
lopidogrel and glycoprotein IIb/IIIa inhibitors on the
ong-term clinical outcomes of patients with ST-segment
levation acute MI remains to be established (2,14,15).
onclusions. Sirolimus-eluting stent implantation for un-
elected patients with ST-segment elevation acute MI
as associated with similar procedural and 30-day out-
omes compared to bare stents, but markedly reduced the
isk of major adverse events and repeat intervention at 10
onths. By providing effective mechanical reperfusion
ith similar results to the current therapeutic standard,
nd decreasing the incidence of late complications, SESs
ppeared as an attractive approach for patients admitted
ith acute MI. The promising results of the present study
arrant further confirmation in the context of a random-
zed trial.
eprint requests and correspondence: Dr. Patrick W. Serruys,
horaxcenter, Bd–406, Dr. Molewaterplein 40, 3015-GD Rot-
erdam, The Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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